Kidney Transplant Rejection clinical trials

Explore recruiting kidney transplant rejection clinical trials.

Recruiting kidney transplant rejection studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Kidney Transplant Rejection trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A seamless Phase 2/3 randomized, open-label study to investigate efficacy and safety of frexalimab versus tacrolimus in adult kidney transplant recipients

Germany, Hungary, Italy, Belgium, Czechia, Finland +6 more

Phase II and Phase III (Integrated) EU CTIS Study details

Long-Term Follow-Up of Patients Who Have Received An Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR-Treg therapy, TX200-TR101) In A Prior Clinical study

Belgium, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

A controlled, open-label post-authorisation efficacy and safety study in imlifidase desensitised kidney transplant patients with positive crossmatch against a deceased donor prior to imlifidase treatment, including non-comparative registry and concurrent reference cohorts

Germany, Sweden, Belgium, Czechia, Austria, Italy +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A single-arm, multi-centre trial to evaluate efficacy and safety of imlifidase in highly sensitised children (1-17 years) receiving a kidney transplant with positive crossmatch against a living or deceased donor converted to negative after imlifidase treatment

Spain, Finland, Sweden, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A prospective, post-authorisation long-term follow up trial of patients previously treated with imlifidase prior to kidney transplantation, including a non-comparative concurrent reference cohort

Spain, Czechia, Belgium, Sweden, France, Netherlands +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

BESTOW-EXTENSION: A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

Spain, Germany, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Kidney Transplant Rejection trials by city

Kidney Transplant Rejection in Toronto Kidney Transplant Rejection in Vancouver Kidney Transplant Rejection in Montreal Kidney Transplant Rejection in Calgary Kidney Transplant Rejection in Edmonton Kidney Transplant Rejection in Ottawa Kidney Transplant Rejection in Winnipeg Kidney Transplant Rejection in Quebec City Kidney Transplant Rejection in Hamilton Kidney Transplant Rejection in Kitchener Kidney Transplant Rejection in London Kidney Transplant Rejection in Halifax Kidney Transplant Rejection in New York Kidney Transplant Rejection in Los Angeles Kidney Transplant Rejection in Chicago Kidney Transplant Rejection in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease